The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.

Gynecol Oncol 2015 Aug 4;138(2):378-82. Epub 2015 Jun 4.

KU Leuven - University of Leuven, University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, B-3000 Leuven, Belgium. Electronic address:

Objectives: New treatment options for advanced and recurrent endometrial carcinoma (EC) are necessary. Epidemiological studies showed that diabetic patients using metformin have reduced risks of endometrial cancer (EC) incidence. Moreover, pre- and clinical studies demonstrated an antitumor effect by metformin, with and without additional treatments, for different solid malignancies. However, cancer cell-autonomous effects of metformin on EC have not been fully characterized yet. The aim of this study was to investigate the effect of metformin, with or without carboplatin, on patient-derived primary endometrioid EC cells xenografted in nude mice, to assess its ability to reduce or impair growth in already established tumors.

Methods: Two xenograft models were established by subcutaneous inoculation of primary endometrioid EC cell suspensions. Tumors were allowed to grow and then mice were treated with metformin (250 mg/kg, daily, p.o.), carboplatin (50 mg/kg, 1×/week, i.p.), or the combination of both compounds at the same concentration as single treatment, for three weeks. Effects of metformin treatment on the tumor mass were determined by tumor growth follow-up. Metformin influences on AMPK/mTOR cell signaling were evaluated by investigating AKT, AMPK and S6 phosphorylation levels.

Results: In vivo, metformin did not affect the growth of EC tumors established from patient-derived primary cultures and the phosphorylation of AKT, AMPK and S6. In addition, no enhanced antitumor effect was determined by combining metformin and carboplatin treatments.

Conclusions: Metformin, at clinically relevant concentrations, did not show effects on the growth of already established tumors. Adding metformin to carboplatin did not have synergistic effects.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.06.006DOI Listing
August 2015
21 Reads

Publication Analysis

Top Keywords

metformin carboplatin
16
primary endometrioid
12
metformin
11
antitumor metformin
8
patient-derived primary
8
effects metformin
8
endometrial carcinoma
8
growth established
8
akt ampk
8
carboplatin
5
growth tumors
4
models established
4
tumors established
4
tumorsmethods xenograft
4
established subcutaneous
4
xenograft models
4
endometrioid cell
4
suspensions tumors
4
metformin affect
4
tumors allowed
4

Similar Publications